Law360, New York (June 07, 2012, 8:50 PM ET) -- The generic-drug industry advised lawmakers reconciling two versions of the U.S. Food and Drug Administration user fee bills to adopt Senate language that would side with generics makers in a fight over getting drug samples from brand-name makers, in a letter released Thursday.
The Generic Pharmaceutical Association asked the lawmakers to include a provision that would prevent brand-name drug makers from refusing to provide samples of their products to companies seeking to replicate the drugs.
At issue are the “risk evaluation and mitigation strategies,” or REMS,...
Generics Industry Pushes Congress On Brand-Name Samples
To view the full article, take a free trial now.
